Mr Gerald Quentin Burnett Jr, PA-C | |
72724 29 Palms Hwy, Suite 103, 29 Palms, CA 92277 | |
(760) 367-5906 | |
Not Available |
Full Name | Mr Gerald Quentin Burnett Jr |
---|---|
Gender | Male |
Speciality | Physician Assistant |
Location | 72724 29 Palms Hwy, Suite 103, 29 Palms, California |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1912012998 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
363A00000X | Physician Assistant | CA 15832 (California) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mr Gerald Quentin Burnett Jr, PA-C 7179 Palo Alto #4, Yucca Valley, CA 92284 Ph: (760) 365-9305 | Mr Gerald Quentin Burnett Jr, PA-C 72724 29 Palms Hwy, Suite 103, 29 Palms, CA 92277 Ph: (760) 367-5906 |
News Archive
A new study reveals that insurance status, marital status, and county-level income may affect the chances of survival in young patients with acute myelogenous leukemia (AML). Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings indicate that efforts are needed to address the social factors that impact critical aspects of health in these patients.
The observed increase in COVID-19 cases coinciding with the reopening of college campuses all over the US has drawn intense scientific attention. A recent paper, by Washington State University researchers, published on the preprint server medRxiv* in September 2020 reports that this threat is directly linked to the holding of in-person sporting events on these campuses.
Results of a new study by researchers at Columbia University's Mailman School of Public Health indicate that a developmental pattern of impulsiveness in young males is linked with gambling problems in late adolescence.
Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that it will be issued U.S. Patent Numbers 7,795,025 and 7,794,704 on Tuesday, September 14th, which continue to extend the company's patent portfolio covering its retinal pigment epithelial (RPE) cell programs.
› Verified 5 days ago